INVENTIVA SA IVA
ADS · ADR · CUSIP 46124U107
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $4.04.
Trends to Q2 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 9 |
| Q4 2022 | 8 |
| Q1 2023 | 10 |
| Q2 2023 | 10 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 2 | 3 |
| Q1 2023 | 3 | 1 |
| Q2 2023 | 4 | 3 |
Biggest buyers
| TWO SIGMA INVESTMENTS, LP | New | +13.6k |
| COMMONWEALTH EQUITY SERVICES, LLC | Added | +6.2k |
| NewEdge Advisors, LLC | Added | +500 |
| UBS Group AG | New | +34 |
Biggest sellers
| Ikarian Capital, LLC | Sold out | -292.6k |
| CITIGROUP INC | Sold out | -23.0k |
| MORGAN STANLEY | Reduced | -4.5k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Invus Global Management, LLC 13G · passive investor +2.8 pts · filed 2025-07-31 | 10.6% |
| Sofinnova Crossover I 13G · exempt (held before listing) +1.4 pts · filed 2026-02-17 | 8.6% |
| Samsara BioCapital, L.P. 13D · may seek influence +1.5 pts · filed 2025-11-19 | 7.4% |
| Andera Partners 13G · passive investor -1.0 pts · filed 2026-10-27 | 6.7% |
| Yiheng Capital Management, L.P. 13G · institution -2.9 pts · filed 2025-11-13 | 5.5% |
Fell to 5% or below in the last year: Deep Track Capital, LP (3.8%, 2026-05-15), New Enterprise Associates 17, L.P. (4.9%, 2026-04-01), GREAT POINT PARTNERS LLC (3.5%, 2026-02-17), EVENTIDE ASSET MANAGEMENT, LLC (4.6%, 2026-02-13), BIOTECHNOLOGY VALUE FUND L P (5.0%, 2025-11-19)
Insider purchases and sales in Q2 2023
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2023.
Holders, Q2 2023
| Manager | Shares | Change |
|---|---|---|
| Yiheng Capital Management, L.P. 0.93% of their portfolio | 2.6m $10.7m | Unchanged |
| NEA Management Company, LLC 0.45% of their portfolio | 1.5m $5.9m | Unchanged |
| BVF INC/IL 0.08% of their portfolio | 686.0k $2.8m | Unchanged |
| COMMONWEALTH EQUITY SERVICES, LLC 0.00% of their portfolio | 20.3k $82.0k | Added +6.2k |
| TWO SIGMA INVESTMENTS, LP 0.00% of their portfolio | 13.6k $55.0k | New |
| MORGAN STANLEY 0.00% of their portfolio | 1.4k $5.7k | Reduced -4.5k |
| NewEdge Advisors, LLC 0.00% of their portfolio | 1.2k $4.8k | Added +500 |
| CWM, LLC 0.00% of their portfolio | 100 $0 | Unchanged |
| UBS Group AG 0.00% of their portfolio | 34 $137 | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |